artificial intelligence
Overview
Artificial intelligence (AI) refers to the simulation of human cognitive processes—including learning, reasoning, and problem-solving—by computational systems, and has emerged as one of the most transformative technological forces in modern biomedicine. In the medical and life sciences context, AI encompasses a broad family of techniques including machine learning (ML), deep learning, natural language processing, and large language models, each enabling computers to identify complex patterns in high-dimensional data that exceed the practical limits of human analysis. Its core value in healthcare lies in its capacity to integrate heterogeneous datasets—from clinical records and medical imaging to multi-omics molecular profiles—into unified predictive and diagnostic frameworks.
The biological significance of AI in medicine is not rooted in a single mechanism but rather in its function as an integrative analytical layer. By processing genomics, transcriptomics, proteomics, and metabolomics data simultaneously, AI-driven models can map disease biology at an unprecedented resolution, linking molecular alterations to clinical phenotypes, treatment responses, and patient outcomes. This positions AI not merely as a computational convenience but as a fundamental infrastructure for precision medicine, enabling the identification of actionable biomarkers, the optimization of drug formulations, the stratification of patient risk, and the acceleration of therapeutic discovery across virtually every disease domain.
Recent Publications Summary
Recent publications on artificial intelligence span education, clinical workflow, consumer perception, diagnostics, and predictive modeling. In medical education, a qualitative study of 10 faculty members from two institutions in the United Arab Emirates examined perspectives on integrating AI into undergraduate medical curricula, using semistructured interviews and thematic analysis guided by the FACETS framework 42594351Aug. In psychiatry, a protocol for a mixed methods systematic review was designed to evaluate whether AI and machine learning interventions can improve continuity of patient care by enhancing monitoring, triage, and resource allocation, while also identifying implementation barriers and facilitators 42555933Aug.
Several studies focused on acceptance, trust, and governance. A participatory qualitative study in Queensland, Australia explored consumer views on “social license” for AI in health care and strategies for achieving public trust and perceived benefit 42550507Aug. In Jordan, researchers developed and validated an Artificial Intelligence Perception questionnaire for mental health consumers, applying principal component analysis to assess construct validity in a sample of 431 participants 42531195Jul. On the implementation side, a framework for post-deployment surveillance of AI medical devices emphasized decision-oriented monitoring and governance-linked corrective action, while an AI-assisted ethical protocol for machine learning in healthcare proposed six clinician-facing principles covering equity, transparency, oversight, privacy, sustainability, and professional education 42319397Jun41795494Mar.
AI was also applied to diagnostic and operational problems. A comparative cost analysis of autonomous AI-based screening for diabetic retinopathy in primary care reported successful completion of most examinations and compared direct and indirect costs against physician-based referral pathways 42532593Jul. In dermatology, a retrospective analysis examined factors affecting the specificity of a convolutional neural network melanoma diagnostic tool, comparing false positives with true negatives in primary care dermoscopic images 42304848Jun. In stroke care, an AI-driven triage system was evaluated for its impact on workflow efficiency and transfer optimization across multiple thrombectomy hubs 41895841Mar.
Predictive and decision-support applications were also prominent in internal medicine and transplant care. A multicenter cohort study developed machine learning models to predict recurrent autoimmune hepatitis after liver transplantation using 62 clinical and laboratory variables, with SHAP analysis used to interpret feature importance at both individual and population levels 42520166Jul. Across broader biomedical development and translational research, reviews highlighted AI and machine learning as enabling tools for predictive modeling, simulation, organ-on-chip experimentation, nanomedicine evaluation, drought-resilient crop improvement, and ophthalmic precision medicine, underscoring AI’s expanding role in data analysis, optimization, and clinically oriented prediction 41592638Jan41747944Feb41662977Feb40685494Jul.
What Changes, What Holds
1. AI is moving from a computational tool to a curricular competency in medicine
NEW DIRECTION Medical education now treats AI not just as something clinicians may use, but as something students may need structured exposure to and faculty readiness for. That extends the baseline’s claim about AI as biomedical infrastructure into training and implementation, while also showing that adoption depends on curricular design, educator buy-in, and the practical translation of AI into undergraduate programs 42594351Aug.
2. Trust and governance are becoming central determinants of AI adoption in health care
NEW DIRECTION Public acceptance, perceived legitimacy, and post-deployment oversight emerge as separate requirements from technical performance, adding a social and regulatory layer to the baseline’s precision-medicine account. The new work implies that AI’s biomedical value will not translate automatically into use; it must also earn consumer trust, satisfy ethical expectations, and remain monitorable after release 42550507Aug42319397Jun.
3. AI is proving useful for operational triage and screening, but its performance still depends on workflow and error control
REINFORCES Diagnostic and triage studies strengthen the baseline’s claim that AI can handle complex pattern recognition in real clinical settings, especially where speed, scale, or access are limiting. At the same time, the melanoma analysis shows that specificity and false positives remain important constraints, so clinical utility depends not only on model accuracy but on how the system is deployed and what downstream pathway it replaces 42532593Jul42304848Jun.
4. AI is expanding as a prediction layer for post-treatment risk and translational experimentation
REINFORCES Risk stratification after liver transplantation fits squarely within the baseline’s description of AI as a tool for linking multivariable biomedical data to patient outcomes, and the broader reviews reinforce its role in modeling, optimization, and experimental acceleration. What remains unsettled is not whether AI can add predictive value, but how generalizable, interpretable, and clinically actionable these models will be across settings 42520166Jul41592638Jan.
Overview update candidates: AI in medical education and governance; consumer trust and post-deployment surveillance as implementation requirements; workflow-aware limits of clinical deployment; expanded predictive use in transplant and translational research.
artificial intelligence
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding artificial intelligence are described as follows:
- Proteomics (Technology) — 6 papers: PMIDs 41936855, 41921727, 41867453, 41848587, etc.
- cardiovascular disease (Disease) — 5 papers: PMIDs 42566559, 42390348, 42299131, 42297461, etc.
- genomics (Other) — 5 papers: PMIDs 41936855, 41921727, 41867453, 41669831, etc.
- machine learning (Technology) — 5 papers: PMIDs 42584723, 42517779, 41944117, 41674557, etc.
- metabolomics (Technology) — 5 papers: PMIDs 41936855, 41921727, 41669831, 41662977, etc.
- breast cancer (Disease) — 4 papers: PMIDs 42541454, 42532480, 41936855, 41616992
- Cancer (Disease) — 4 papers: PMIDs 42509546, 42496805, 42496586, 42285091
- deep learning (Technology) — 4 papers: PMIDs 42507684, 42482638, 41944117, 41674557
- diabetes (Disease) — 4 papers: PMIDs 42532593, 42516116, 42475533, 40685494
- lung cancer (Disease) — 4 papers: PMIDs 42532480, 42493517, 41789674, 41789644
- transcriptomics (Technology) — 4 papers: PMIDs 41936855, 41921727, 41867453, 41616992
- biomarker discovery (Other) — 3 papers: PMIDs 41894385, 41867453, 41855081
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study artificial intelligence:
- deep learning (Technology) — 11 papers: PMIDs 42586983, 42517779, 42505016, 42503659, etc.
- patient (Organism) — 10 papers: PMIDs 42547870, 42541590, 42529767, 42520166, etc.
- machine learning (Technology) — 8 papers: PMIDs 42584723, 42562389, 42560990, 42555933, etc.
- ChatGPT (Technology) — 5 papers: PMIDs 42594351, 42578851, 42573794, 42541590, etc.
- large language model (Technology) — 4 papers: PMIDs 42475255, 42361541, 42342241, 42314146
- Large Language Models (Technology) — 4 papers: PMIDs 42573794, 42560990, 42481185, 41903776
- multiomics (Technology) — 4 papers: PMIDs 42562589, 42509546, 42276326, 42262677
- natural language processing (Technology) — 4 papers: PMIDs 42594964, 42560990, 42529767, 42505016
- transformer (Technology) — 4 papers: PMIDs 42586983, 42519894, 42496586, 41762798
- AI systems (Technology) — 3 papers: PMIDs 42573583, 42550507, 41903776
- ChatGPT 3.5 (Technology) — 3 papers: PMIDs 41795494, 41747019, 41744196
- Decision Curve Analysis (Technology) — 3 papers: PMIDs 42524724, 42495152, 42324747
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to artificial intelligence include:
- diabetic retinopathy (Disease) — 3 papers: PMIDs 42532593, 42517779, 42243112
- Baseline biomarkers (Clinical Metric) — 2 papers: PMIDs 41936855, 41616992
- cancer cell (Cellular Component) — 2 papers: PMIDs 42509447, 41855081
- cancer immunotherapy (Biological Process) — 2 papers: PMIDs 41867453, 41789644
- fracture detection (Biological Process) — 2 papers: PMIDs 42527905, 42301372
- macular degeneration (Disease) — 2 papers: PMIDs 42527415, 42243112
- pembrolizumab (Therapy) — 2 papers: PMIDs 42342409, 41593888
- Peptides (Protein) — 2 papers: PMIDs 41926038, 41674557
- Targeted Cancer Therapy (Therapy) — 2 papers: PMIDs 41789674, 41789644
- therapeutic drug targets (Other) — 2 papers: PMIDs 42299131, 42276326
- 30-day, 90-day and 180-day risks of all-cause and index-disease hospitalisations (Clinical Metric) — 1 paper: PMIDs 42128515
- 5-HT1F receptor agonists (Protein) — 1 paper: PMIDs 41864040
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with artificial intelligence include:
- Accuracy (Clinical Metric) — 7 papers: PMIDs 42532480, 42530427, 42524724, 42507684, etc.
- sensitivity (Clinical Metric) — 6 papers: PMIDs 42541590, 42532480, 42527415, 42492497, etc.
- F1 score (Clinical Metric) — 5 papers: PMIDs 42524724, 42507684, 42492497, 42481185, etc.
- Area Under the Curve (Clinical Metric) — 4 papers: PMIDs 42541590, 42527415, 42495152, 42436095
- precision (Clinical Metric) — 4 papers: PMIDs 42584723, 42524724, 42492497, 42475255
- specificity (Clinical Metric) — 4 papers: PMIDs 42541590, 42532480, 42527415, 42492497
- correlation (Other) — 3 papers: PMIDs 42579383, 42527765, 42516004
- hazard ratio (Clinical Metric) — 3 papers: PMIDs 42495152, 42390348, 42315311
- P-value (Other) — 3 papers: PMIDs 42495152, 42493517, 42413962
- participants (Other) — 3 papers: PMIDs 42561383, 42532593, 42488974
- positive and negative predictive values (Clinical Metric) — 3 papers: PMIDs 42541590, 42527415, 42324609
- Age (Other) — 2 papers: PMIDs 42562389, 42315311
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding artificial intelligence are summarized below:
- personalized medicine (Other) — 6 papers: PMIDs 42479705, 42324441, 41867453, 41848587, etc.
- precision oncology (Therapy) — 5 papers: PMIDs 42509546, 41936855, 41930252, 41921727, etc.
- prospective validation (Other) — 4 papers: PMIDs 42520166, 42496805, 42495152, 41616992
- Baseline biomarkers (Clinical Metric) — 3 papers: PMIDs 41921727, 41918200, 41848587
- human oversight (Other) — 3 papers: PMIDs 42361541, 42324609, 41903776
- clinical decision-making (Other) — 2 papers: PMIDs 42586897, 42324608
- clinicians (Other) — 2 papers: PMIDs 42560990, 42517779
- decision-support tool (Other) — 2 papers: PMIDs 42547870, 42235465
- efficiency (Other) — 2 papers: PMIDs 42324608, 41125298
- equity (Other) — 2 papers: PMIDs 42594964, 42571005
- external validation (Other) — 2 papers: PMIDs 42562389, 42541590
- Formulation Development (Other) — 2 papers: PMIDs 42067169, 41579967